MGMT-guided treatment

What it is

MGMT-guided treatment uses a tumor's MGMT promoter methylation status to help decide whether and how to use the chemotherapy drug temozolomide. Because MGMT methylation predicts a better response to temozolomide, this marker can influence treatment choices — particularly in older patients.

Understanding MGMT-guided treatment

MGMT status is a predictive marker: tumors with a methylated (silenced) MGMT gene respond better to temozolomide, while those without methylation respond less well. This information can guide decisions, especially where the balance of benefits and burdens matters most. In older patients with glioblastoma, for example, MGMT status can help decide between options — a methylated tumor may favor including temozolomide (which is likely to help), while for an unmethylated tumor, radiation alone (or a different emphasis) might be considered, since temozolomide's benefit is smaller. In standard treatment for younger, fit patients, temozolomide is generally used regardless, but MGMT status still informs prognosis and expectations. MGMT-guided treatment exemplifies using a molecular marker to personalize therapy. The specifics are decided with the oncology team based on the individual situation. Understanding MGMT-guided treatment in gliomas clarifies how a marker informs temozolomide decisions.

Why it matters

Understanding MGMT-guided treatment helps patients and families see how a tumor's MGMT status personalizes treatment — informing whether temozolomide is likely to help, particularly relevant for older patients' decisions.